ID   DM459
AC   CVCL_IS51
SY   Duke Melanoma 459
DR   GEO; GSM276768
DR   Wikidata; Q54831232
RX   PubMed=9241074;
RX   PubMed=11520076;
CC   From: Duke University Medical Center; Durham; USA.
CC   Omics: Transcriptomics; Microarray.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 10-04-25; Version: 6
//
RX   PubMed=9241074; DOI=10.1002/(SICI)1097-0142(19970801)80:3<401::AID-CNCR8>3.0.CO;2-U;
RA   Abdel-Wahab Z., Weltz C., Hester D., Pickett N., Vervaert C.,
RA   Barber J.R., Jolly D.J., Seigler H.F.;
RT   "A phase I clinical trial of immunotherapy with interferon-gamma
RT   gene-modified autologous melanoma cells: monitoring the humoral immune
RT   response.";
RL   Cancer 80:401-412(1997).
//
RX   PubMed=11520076; DOI=10.1006/cimm.2001.1809;
RA   Zennadi R., Abdel-Wahab Z., Seigler H.F., Darrow T.L.;
RT   "Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells:
RT   requirement of both HLA-DR15 and Fas antigens on melanomas for their
RT   lysis by Th2 cells.";
RL   Cell. Immunol. 210:96-105(2001).
//